To the Editor,
Nitrous oxide (N 2 O) has been part of anesthetic practice for almost 200 years. However, administration of the gas has declined dramatically over the last decade, perhaps because of an incidental finding of the N 2 O in the gas mixture for anesthesia (ENIGMA) trial. 1 The ENIGMA trial results suggested a possible association between N 2 O use and cardiac morbidity following noncardiac surgery (adjusted odds ratio, 1.59; 95% confidence interval [CI], 1.01 to 2.51). The ENIGMA trial was not designed or adequately powered to detect a difference in cardiac events and was criticized for having different inspired oxygen levels in the N 2 O and control groups. These concerns were specifically addressed in a follow-up trial (ENIGMA-II) that found no significant difference in cardiac events (relative risk, 0.96; 95% CI 0.83 to 1.12). 2 The roles of these two studies in affecting practice and reasons for abandoning N 2 O were raised at one of our regular ''Journal Club'' discussions.
The purpose of this survey was to identify the current views on N 2 O among practicing anesthesiologists and trainees. Because there appeared to have been a decline in the use of N 2 O following ENIGMA, we specifically questioned the roles the ENIGMA and ENIGMA-II trials played in shaping practice. This study was approved by the Hamilton Integrated Research Ethics Board on 7 November 2016.
We developed an 11-item English-language questionnaire to collect demographics of respondents and perceptions of N 2 O as an anesthetic gas through various time periods between ENIGMA and ENIGMA-II (see the Electronic Supplementary Material for the instrument and full results). This survey was distributed through the Canadian Anesthesiologists' Society mailing list of anesthesiologists and trainees across the country.
We received 383 responses to our survey with 365 of 1785 (20%) anesthesiologists and 16 of 634 (3%) residents. Of those responding, 330 of 383 (86%) completed their anesthesia training in Canada and 366 of 382 (95%) practiced anesthesia a minimum of two to three times per week (Table 1) .
Although prone to recall bias, ENIGMA appeared to have decreased the frequency of clinical N 2 O use. There was no resurgence of N 2 O use following publication of ENIGMA-II although it was a large, international trial. A total of 310 of 380 (82%) felt that the results of ENIGMA-II led to no change in their N 2 O usage. When asked, those who decreased or stopped using N 2 O following ENIGMA reported diverse reasons with postoperative nausea and vomiting (PONV) ranked the highest with 169 responses. This was despite the fact that the risk was almost completely mitigated by PONV prophylaxis in ENIGMA-II. 3 Other responses included N 2 O being environmentally unfriendly (with an atmospheric lifetime of 114 years), 4 being inferior to newer agents, and individuals being unconvinced of current evidence of safety. It is difficult to determine the extent that ENIGMA alone affected N 2 O use but our survey suggests that the results of ENIGMA-II did not strongly modify clinical practice.
While 318 of 380 (84%) surveyed felt there was still a role for N 2 O in anesthesia, it appears to be used infrequently. Only 121 of 381 (32%) respondents reported using N 2 O two to three times per week or more often. Qualitatively, many referred to its usefulness in obstetric and pediatric populations, which were not specifically addressed in our survey. We believe that though N 2 O usage has declined, it retains characteristics beneficial to patients and should remain in clinical practice. Our survey suggests that the previous association of N 2 O and cardiovascular complications is unlikely to have been the only factor driving the clinical decision to decrease its usage. 
